By: Michaela Dowling, Kiera Liblik
In this randomized controlled trial, in patients with PIK3CA -mutated advanced breast cancer, the addition of inavolisib to a palbociclib-fulvestrant regimen significantly extended progression-free survival compared to palbociclib-fulvestrant alone.